Last reviewed · How we verify
GTX-104
GTX-104 is a small molecule that targets the PD-1/PD-L1 pathway.
GTX-104 is a small molecule that targets the PD-1/PD-L1 pathway. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | GTX-104 |
|---|---|
| Sponsor | Grace Therapeutics Inc. |
| Drug class | Immune checkpoint inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
GTX-104 works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thus enhancing the immune response against cancer cells.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Pneumonitis
- Colitis
- Hypothyroidism
Key clinical trials
- Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH (PHASE3)
- Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |